Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Madrigal Pharmaceuticals ...

    NASDAQ: MDGL · Real-Time Price · USD
    271.38
    3.82 (1.43%)
    At close: May 27, 2025, 3:59 PM
    275.00
    1.33%
    After-hours: May 27, 2025, 04:21 PM EDT
    1.43%
    Bid 271.57
    Market Cap 6.03B
    Revenue (ttm) 317.38M
    Net Income (ttm) -391.59M
    EPS (ttm) -17.85
    PE Ratio (ttm) -15.2
    Forward PE -862.55
    Analyst Strong Buy
    Ask 279
    Volume 240,531
    Avg. Volume (20D) 361,078
    Open 270.55
    Previous Close 267.56
    Day's Range 266.17 - 273.99
    52-Week Range 200.63 - 377.46
    Beta -0.92

    About MDGL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol MDGL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for MDGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 months ago
    +14.99%
    Madrigal Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
    4 months ago
    -10.39%
    Madrigal Pharmaceuticals shares are trading lower after the company reported preliminary Q4 and FY24 financial results.
    news image

    1 week ago · seekingalpha.com

    In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals

    Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include pote...

    news image

    3 weeks ago · seekingalpha.com

    Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra

    Madrigal Pharmaceuticals has a first-mover advantage in the huge MASH market due to the approval of Rezdiffra just over a year ago. The initial rollout of the compound is encouraging, and the company ...

    news image

    3 weeks ago · seekingalpha.com

    Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript

    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive...

    news image

    3 weeks ago · zacks.com

    Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

    MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

    news image

    3 weeks ago · zacks.com

    Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates

    Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.

    news image

    2 months ago · zacks.com

    Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?

    Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

    news image

    2 months ago · seekingalpha.com

    Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)

    Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P...

    Add to Watchlist